My watch list
my.bionity.com  
Login  

Enoxaparin



Enoxaparin
Systematic (IUPAC) name
6-[5-acetylamino-4,6-dihydroxy-2- (sulfooxymethyl)tetrahydropyran-3-yl] oxy-3- [5-(6-carboxy-4,5-dihydroxy-3- sulfooxy-tetrahydropyran-2-yl)oxy-6-(hydroxymethyl)- 3-sulfoamino-4-sulfooxy-tetrahydropyran-2-yl] oxy-4-hydroxy-5-sulfooxy-tetrahydropyran-2- carboxylicacid
Identifiers
CAS number 9005-49-6
ATC code B01AB05
PubChem 772
DrugBank APRD00068
Chemical data
Formula (C26H40N2O36S5)n
Mol. mass 4500 daltons (average)
Pharmacokinetic data
Bioavailability 92%
Protein binding 80% bound-albumin
Metabolism primarily by liver by desulfation and/or depolymerization
Half life 4.5 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.

B

Legal status
Routes Subcutaneous (SC) Injection and intervenous (IV) per package insert

Enoxaparin is a low molecular weight heparin manufactured by Sanofi-Aventis. It is marketed as Lovenox or Clexane. Enoxaparin injections are derived from the intestinal mucosa of pigs. Enoxaparin is used to prevent and treat deep vein thrombosis or pulmonary embolism, and is given as a subcutaneous injection (by a health care provider or the patient). Its use is evolving in acute coronary syndromes (ACS).

Additional recommended knowledge

Contents

Indications

In the UK, enoxaparin is approved for five indications:

In the United States, enoxaparin is FDA approved for eight indications:

  • Prophylaxis of DVT in medically ill patient,
  • Total hip & knee replacement,
  • Extended hip-replacement,
  • Abdominal surgery.
  • Treatment of DVT with or with out PE inpatient and
  • Treatment of DVT inpatient, with ACS, including STEMI.


Mechanism of action

Enoxaparin binds to and accelerates the activity of antithrombin III. By activating antithrombin III, enoxaparin preferentially potentiates the inhibition of coagulation factors Xa and IIa. The anticoagulant effect of enoxaparin can be directly correlated to its ability to inhibit factor Xa. Factor Xa catalyzes the conversion of prothrombin to thrombin, so enoxaparin’s inhibition of this process results in decreased thrombin and ultimately the prevention of fibrin clot formation.

Monitoring

  • Enoxaparin does not affect the INR, PT or aPTT
  • Anti-factor Xa levels can be measured, and are often used to monitor enoxaparin activity

Pregnancy

  • Category B: enoxaprin is safe for use in the second trimester as it does not cross the placenta

Side effects

Reversal Agent

  • Protamine, although not as effective at reversal as it is for heparin due to more activity at the Xa clotting factor (enoxaparin); as heparin has both Xa and IIa. Protamine sulfate will reverse enoxaparin by 66% per package insert.

Availability

100 mg/mL

  • Prefilled Syringes: 30mg/0.3mL, 40mg/0.4mL
  • Graduated Prefilled Syringes: 60mg/0.6mL, 80mg/0.8mL, 100mg/1mL
  • Multiple Dose Vials: 300mg/3.0mL

150mg/mL

  • Graduated Prefilled Syringes: 120mg/0.8mL, 150mg/1mL
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Enoxaparin". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE